[Skip to Content]
[Skip to Content Landing]
Views 361
Citations 0
Editorial
February 2017

OpicaponeA Novel Adjunct for an Old Standard

Author Affiliations
  • 1Department of Neurology, The University of Texas McGovern Medical School at Houston
JAMA Neurol. 2017;74(2):153-154. doi:10.1001/jamaneurol.2016.5012

Parkinson disease (PD) is the second most common, chronic, progressive, neurodegenerative disease worldwide and is considered a treatable and manageable disorder with an armamentarium of effective medical, surgical, and physical therapies available. Nonetheless, the dopamine precursor, levodopa, remains the standard of therapy for PD.1 As the disease progresses, however, and the severity of dopamine depletion increases, the duration of efficacy of levodopa therapy progressively shortens, giving rise to fluctuations in response. Motor fluctuations can manifest as a wearing-off effect, dyskinesias, or an unpredictable on-off response with sudden freezing. Almost 40% of patients will experience motor fluctuations after 4 to 6 years of treatment, which will increase to at least 70% after long-term treatment (>9 years).2 This finding is even more striking in patients with young-onset PD (symptom onset before 40 years of age), who have a reported 90% prevalence of dyskinesias and motor fluctuations 5 years after initiation of levodopa therapy.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×